TOPLINE: Ustekinumab exhibited higher persistence rates as a second-line therapy than anti–tumour necrosis factor (anti-TNF) treatment in patients with Crohn’s disease. Clinical remission rates with ustekinumab improved progressively, reaching 100% by 5 years. METHODOLOGY: Researchers conducted this retrospective observational study of a prospective database to compare the persistence rates of ustekinumab as a second-line treatment ...
.png)
55W 14th St Ste 101, Helena, MT, 59601 US
+1 (406) 319 1601
news.in.usa@olahost.top
Copyright © 2024 olasport. All Rights Reserved
